periodtrader
Markets/investing analyst posting on small‑/mid‑cap strategies, fund commentaries, and undervalued international small caps.
Netflix Ad Tier Set to Double Revenue, Price Target $700
Netflix's ad-supported tier is crushing it. Analysts now project its ad revenue will DOUBLE to ~$3B this year. Bullish outlook has one firm raising its price target to $700. 📈 Streaming
BEHL Q4 2025
Beijing Enterprises Holdings (BEHL) just dropped its Q4 2025 results. Key figures on revenue, profit, and dividends are in. A look at performance across gas, water, and brewery segments. Earnings
NBTXR3 Surpasses 70% Enrollment, on Track For
$NBTX update: Their lead cancer drug NBTXR3 is now over 70% enrolled in its crucial Phase 3 trial. Target: complete enrollment by end of 2025. With cash into late 2027, they're funded to reach this major milestone. Biotech
Conagra Thrives on Value Shift as Premium Sales Falter
Conagra's Q3 shows the "bracket consumer" in action: shoppers trading down to value brands like Banquet, pressuring premium lines. Sales dipped but margins & EPS grew. Portfolio built for this shift. Earnings
Feb Job Gains Signal Recovery, Wage Growth Slows
The big jobs rebound (275k in Feb) is mostly a recovery from Jan's storms & strikes. Wage growth cooled, which is key. Labor market looks solid but normalizing. JobsReport
March Jobs Rise, Participation Dips; Fed Stays Patient
March jobs report is a mixed bag. Blockbuster +303K payroll growth shows strength, but a dip in labor force participation signals some underlying softness. The Fed will likely stay patient. JobsReport
March Jobs Surge, yet Participation Drops, Fed Mixed Signal
March jobs blew past expectations (+303K!), but look closer. Prime-age worker participation fell & part-time work spiked. A mixed signal for the Fed. JobsReport
Tech Dividend ETF Offers Stable Income and Growth
Income investors, meet your tech solution. $TDIV targets profitable tech giants that pay & grow dividends, offering a smoother ride than pure growth funds. Ideal for long-term income + sector growth. Dividends
Trump's Pharma Tariff Won't Lower Prices, Study Finds
Trump's proposed 100% tariff on pharma imports would have limited impact, analysis says. Why? 68% of U.S. prescription drugs are already made domestically. Prices are driven by patents & rebates, not import costs. Healthcare
Check Point's Discounted Stock Offers Compelling Cybersecurity Value
Check Point stock trades at a big discount to cybersecurity peers. New analysis argues its elite platform, strong profits, & cloud shift make it a compelling value play. $CHKP Cybersecurity
Okeanis Eco Tankers: Geopolitical
Okeanis Eco Tankers ($OET) is now a geopolitical play. Strong fleet & finances, but its boom hinges on Red Sea disruptions extending voyages. A top-tier bet on volatile trade routes. shipping